CA2461248A1 - Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a - Google Patents
Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a Download PDFInfo
- Publication number
- CA2461248A1 CA2461248A1 CA 2461248 CA2461248A CA2461248A1 CA 2461248 A1 CA2461248 A1 CA 2461248A1 CA 2461248 CA2461248 CA 2461248 CA 2461248 A CA2461248 A CA 2461248A CA 2461248 A1 CA2461248 A1 CA 2461248A1
- Authority
- CA
- Canada
- Prior art keywords
- towards
- receptor
- compound
- dopamine
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000004031 partial agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 46
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 24
- 208000010877 cognitive disease Diseases 0.000 claims abstract 12
- 230000004770 neurodegeneration Effects 0.000 claims abstract 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 11
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 claims 22
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 claims 22
- 102000005962 receptors Human genes 0.000 claims 22
- 108020003175 receptors Proteins 0.000 claims 22
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 11
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 11
- 102000015554 Dopamine receptor Human genes 0.000 claims 11
- 108050004812 Dopamine receptor Proteins 0.000 claims 11
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 10
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 10
- 108010062431 Monoamine oxidase Proteins 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 10
- 229960004502 levodopa Drugs 0.000 claims 10
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 8
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 8
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 8
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 8
- 239000002207 metabolite Substances 0.000 claims 8
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 6
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 4
- 229960004851 pergolide Drugs 0.000 claims 4
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 4
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 claims 4
- 229960002776 pipamperone Drugs 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 claims 3
- 229960003678 selegiline hydrochloride Drugs 0.000 claims 3
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 2
- VGIGHGMPMUCLIQ-UHFFFAOYSA-N LSM-2183 Chemical compound C1=CC(F)=CC=C1N1CCN(CCCN2S(C=3C=CC=C4C=CC=C2C=34)(=O)=O)CC1 VGIGHGMPMUCLIQ-UHFFFAOYSA-N 0.000 claims 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 2
- 229960000911 benserazide Drugs 0.000 claims 2
- 229960002802 bromocriptine Drugs 0.000 claims 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 2
- 229960004596 cabergoline Drugs 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 229950002951 fananserin Drugs 0.000 claims 2
- 229960003980 galantamine Drugs 0.000 claims 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 2
- 229960003587 lisuride Drugs 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 229960003089 pramipexole Drugs 0.000 claims 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 2
- 229960001879 ropinirole Drugs 0.000 claims 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims 1
- OGJGQVFWEPNYSB-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-1H-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C3=CC=CN=C3NC=2)CC1 OGJGQVFWEPNYSB-UHFFFAOYSA-N 0.000 claims 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 1
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 claims 1
- ZFZPJDFBJFHYIV-UHFFFAOYSA-N 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)C(=O)CC21CCCC2 ZFZPJDFBJFHYIV-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 claims 1
- 229950000388 amperozide Drugs 0.000 claims 1
- 229960005245 asenapine Drugs 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229960003532 fluspirilene Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 229950010634 ocaperidone Drugs 0.000 claims 1
- -1 olanzepine Chemical compound 0.000 claims 1
- 229960001057 paliperidone Drugs 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 229950004554 tiospirone Drugs 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims 1
- 229960004496 zotepine Drugs 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 abstract 6
- 230000003042 antagnostic effect Effects 0.000 abstract 3
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 2
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2461248 CA2461248C (fr) | 2003-12-02 | 2004-03-18 | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a |
| CA 2487529 CA2487529A1 (fr) | 2003-12-02 | 2004-11-15 | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a |
| DE602004026781T DE602004026781D1 (de) | 2003-12-02 | 2004-12-02 | Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonist |
| DK04801138.1T DK1708790T3 (da) | 2003-12-02 | 2004-12-02 | Anvendelse af pipamperon af en D2-receptorantagonist eller serotonin/dopaminantagonist til behandling af psykotiske sygdomme |
| EP04801138A EP1708790B1 (fr) | 2003-12-02 | 2004-12-02 | Utilisation de pipamperone et d'un antagoniste des recepteurs d2 ou d'un antagoniste a la dopamine et a la serotonine pour le traitement de troubles psychotiques |
| PCT/BE2004/000172 WO2005053796A1 (fr) | 2003-12-02 | 2004-12-02 | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a, |
| HR20100376T HRP20100376T1 (hr) | 2003-12-02 | 2004-12-02 | Uporaba pipamperona i antagonista d2-receptora ili antagonista serotonin/dopamina za liječenje psihotičnih poremećaja |
| PT04801138T PT1708790E (pt) | 2003-12-02 | 2004-12-02 | Utilizaão de pipamperona e de um antagonista dos receptores d2 ou de um antagonista da dopamina e da serotonina para o tratamento de transtornos psicëticos |
| SI200431439T SI1708790T1 (sl) | 2003-12-02 | 2004-12-02 | Uporaba pipamerona in d receptorskega antagonista kot serotonin dopamin antagonista za zdravljenjepsihičnih nepravilnosti |
| CA002547639A CA2547639A1 (fr) | 2003-12-02 | 2004-12-02 | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a, |
| AT04801138T ATE464901T1 (de) | 2003-12-02 | 2004-12-02 | Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen |
| JP2006541759A JP4571645B2 (ja) | 2003-12-02 | 2004-12-02 | Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用 |
| RSP-2010/0323A RS51331B (sr) | 2003-12-02 | 2004-12-02 | Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja |
| ES04801138T ES2343962T3 (es) | 2003-12-02 | 2004-12-02 | Uso de pipamperona y un antagonista de receptores d2 o un antagonista de serotonina/dopamina para el tratamiento de trastornos psicoticos. |
| PL04801138T PL1708790T3 (pl) | 2003-12-02 | 2004-12-02 | Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych |
| US10/580,962 US8304431B2 (en) | 2003-12-02 | 2004-12-02 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP10159625A EP2272514A1 (fr) | 2003-12-02 | 2004-12-02 | Utilisation d'une faible dose de pipamperone et d'un deuxième agent actif dans le traitement des maladies neurodégénératives |
| CY20101100611T CY1111017T1 (el) | 2003-12-02 | 2010-07-05 | Χρηση πιπαμπερονης και ενος ανταγωνιστη d-2 υποδοχεα ή ανταγωνιστη σεροτονινης/ντοπαμινης για την θεραπεια ψυχωτικων διαταραχων |
| US12/924,615 US20110136865A1 (en) | 2003-12-02 | 2010-09-30 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US13/065,638 US20110207776A1 (en) | 2003-12-02 | 2011-03-25 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2451798A CA2451798C (fr) | 2003-12-02 | 2003-12-02 | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a |
| CA2,451,798 | 2003-12-02 | ||
| EP04447001.1 | 2004-01-05 | ||
| EP04447001 | 2004-01-05 | ||
| CA 2461248 CA2461248C (fr) | 2003-12-02 | 2004-03-18 | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2461248A1 true CA2461248A1 (fr) | 2005-06-02 |
| CA2461248C CA2461248C (fr) | 2009-12-22 |
Family
ID=34623380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2461248 Expired - Fee Related CA2461248C (fr) | 2003-12-02 | 2004-03-18 | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2461248C (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855195B2 (en) | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7884096B2 (en) | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US8304431B2 (en) | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| WO2021139874A1 (fr) * | 2020-01-06 | 2021-07-15 | Anima | Prévention et traitement de troubles cognitifs |
-
2004
- 2004-03-18 CA CA 2461248 patent/CA2461248C/fr not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855195B2 (en) | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7884096B2 (en) | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US8304431B2 (en) | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| WO2021139874A1 (fr) * | 2020-01-06 | 2021-07-15 | Anima | Prévention et traitement de troubles cognitifs |
| WO2021140103A1 (fr) * | 2020-01-06 | 2021-07-15 | Anima | Prévention et traitement de troubles cognitifs |
| CN115279356A (zh) * | 2020-01-06 | 2022-11-01 | 安尤罗泰克Ip私人有限公司 | 认知障碍预防和治疗 |
| AU2021206771B2 (en) * | 2020-01-06 | 2025-03-06 | Aneurotech Bv | Cognitive disorder prevention and therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2461248C (fr) | 2009-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009514929A (ja) | 閉経前の性的欲求障害の治療のためのフリバンセリンの使用 | |
| WO2003024456A1 (fr) | Methodes de traitement et de prevention des migraines | |
| UA72783C2 (en) | Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit | |
| JP2009513713A5 (fr) | ||
| JPWO1996009069A1 (ja) | ５ｈｔ▲下３▼拮抗剤の新規医薬用途 | |
| JP2005505539A (ja) | パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 | |
| CA2450787C (fr) | Combinaison d'ingredients actifs pour substance pharmacologique toxicomanogene ou therapie contre les substances intoxicantes | |
| CA2521182A1 (fr) | Composition permettant d'ameliorer la cognition et la memoire | |
| MX2009002311A (es) | Composiciones farmaceuticas para tratamiento de infecciones fungales. | |
| JP2016505050A5 (fr) | ||
| JP6929860B2 (ja) | 手湿疹の治療 | |
| CA2461248A1 (fr) | Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a | |
| MX2007012300A (es) | Uso de nefopam y analogos del mismo para el tratamiento de un sindrome caracterizado por dolor cronico y fatiga. | |
| JP2004535463A (ja) | 心不全処置のための複合治療 | |
| CZ2004524A3 (cs) | Agonisté nikotinového acetylcholinového receptoru v léčbě syndromu neklidných nohou | |
| CA2228813A1 (fr) | Inhibiteur de la dependance / de la resistance a l'egard des analgesiques narcotiques | |
| CZ2004739A3 (cs) | Použití desoxypeganinu k ošetřování klinické deprese | |
| DE60019968D1 (de) | Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten | |
| JP2002504134A (ja) | 疼痛を治療するためのドラフラジン類似体の使用 | |
| JPH0564124B2 (fr) | ||
| TW201841635A (zh) | 用於治療抑鬱症之組合物及方法 | |
| KR20000029647A (ko) | 양극성장애의치료방법 | |
| JPS625923A (ja) | アレルギ−性疾患治療剤 | |
| JPWO1999008675A1 (ja) | 過敏性腸症候群の治療剤 | |
| KR101086895B1 (ko) | 시부트라민 및 티옥트산을 포함하는 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140318 |